VIR is expected to report earnings to fall 44.07% to -87 cents per share on February 20
Q4'24
Est.
$-0.87
Q3'24
Missed
by $0.51
Q2'24
Missed
by $0.13
Q1'24
Beat
by $0.57
Q4'23
Beat
by $0.22
The last earnings report on October 31 showed earnings per share of -155 cents, missing the estimate of -104 cents. With 3.75M shares outstanding, the current market capitalization sits at 1.01B.
a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases